BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lymphocyte
,
Biofuel
,
Ciprofibrate
,
rs7903146
,
PPARA
,
glucose metabolic process
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
splice acceptor sites
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Chronic myeloid leukemia K562 cells with aCP1-2 combined siRNA knockdown
Explore Curated Studies Results
Literature
Most Relevant Literature
FUBP1 is a general splicing factor facilitating 3' splice site recognition and splicing of long intr…
The polyA tail facilitates splicing of last introns with weak 3' splice sites via PABPN1.
XAP5 CIRCADIAN TIMEKEEPER specifically modulates 3' splice site recognition and is important for cir…
Inducible nuclear import by TetR aptamer-controlled 3' splice site selection.
SPAG6 c.900 T>C affects boar semen quality and blood-testis barrier function by creating a new splic…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and C…
Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX49…
SMN Circular RNAs as Potential Biomarkers for the Therapeutic Response to Nusinersen in Spinal Muscu…
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ